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ABSTRACT
We report a rare case of acute disseminated encephalomyelitis (ADEM) secondary to a primary Epstein-Barr (EBV) infection, in a 22-year-
old male. Symptomatic infectious mononucleosis and ADEM are both quite uncommon conditions in this age group.
LEARNING POINTS
• ADEM is a very rare CNS disorder; it is more common in childhood but can also be described in adults.
• The clinical evaluation must focus on the presence of recent signs of infection or vaccination.
•	 A	normal	cerebral	scan	does	not	rule	out	the	disease	and	MRI	must	be	performed	to	confirm	the	diagnoses.	
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INTRODUCTION
Acute disseminated encephalomyelitis (ADEM) is a very rare condition, more common in childhood than in adults with an estimated 
incidence	of	0.4/100,000	per	year.	It	is	an	inflammatory	and	autoimmune	process	most	often	triggered	by	an	infection	(viral	or	bacterial)	or	
vaccination. The clinical symptoms are polymorphous, consisting of motor disorders, seizures, cranial nerve paralysis, altered mental status 
and	general	signs.	The	diagnosis	must	be	confirmed	by	cerebro–medullary	MRI	showing	multifocal	demyelinating	lesions	in	the	brain	or	the	
spinal cord. Any unexplained encephalomyelitis pattern should always evoke the suspicion of ADEM spectacular. Clinical improvement with 
either	intravenous	corticosteroids	or	immunoglobulins	has	been	reported	but	the	morbi-mortality	remains	significant.
CASE REPORT 
A 22-year-old man, with no previous relevant medical history, was admitted to the Emergency Department for gait disorders and urinary 
retention over the last 48 hours. One week earlier, the patient presented fever, headaches and nasal congestion. Upon admission, blood 
pressure was 120/50 mmHg, heart rate was 80/min regular; he was afebrile and saturating well on room air. The neurological examination 
European Journal
of Case Reports in
Internal Medicine
DOI: 10.12890/2019_001094 European Journal of Case Reports in Internal Medicine © EFIM 2019
revealed	paresis	of	the	lower	limbs	and	abolition	of	patellar	reflexes	preceding	the	development	of	sharp	reflexes	in	the	upper	extremities.	
Hypoaesthesia up to D10 and urinary retention were also found. The rest of the physical examination was normal. Laboratory tests showed 
lymphocyte-dominant hyperleukocytosis at 12,680/mm3, elevated C-reactive protein (CRP) and elevated liver enzymes (TGO 213 U/l, 
TGP	426	U/l,	Gamma	GT	143	U/l,	alkaline	phosphatase	276	U/l).	The	initial	brain	scan	was	normal.	The	cerebrospinal	fluid	(CSF)	showed	
a predominantly neutrophilic leukorachia (1,746/mm3 leukocytes, 100% neutrophilic), red blood cells (591/mm3), hyperproteinorachia 
(2.140 g/l) and normal glycorrhachia. In the context of an infectious encephalitis, empiric antiviral and antibiotic treatment was immediately 
initiated with IV acyclovir, ceftriaxone and ampicillin. The patient was transferred to the intensive care unit. A few hours later, he developed 
paresis of the upper extremities, swallowing disorders and respiratory congestion requiring temporary mechanical ventilation.
Both	cerebral-MRI	and	medullary-MRI	were	ordered.	They	showed	multiple	T2-FLAIR	non-confluent	intramedullary	hyperintensity	lesions	
extended to the whole spinal cord (Figs. 1A and 1B). A second lumbar puncture, aiming to determine the presence of oligonucleotide bands 
and for viral PCR (HSV, VZV, CMV, adenovirus and enterovirus), was performed, and this showed the presence of Epstein-Barr (EBV) viral 
DNA. Laboratory tests were completed with serologies for borreliosis, listeriosis, CMV, herpes, VZV and HIV; these were all negative except 
for EBV, which came back positive (IgM and IgG). 
Figure 1. A. T2R-weighted medullary MRI in the sagittal plane: 
medullary lesions of centromedullary topography (white arrows) and 
hyperintensity extending over the entire cervical-dorsal marrow to the 
cone terminal. Normal calibre of the spinal cord. 
B. After injection of contrast product, on the appearance of some 
medullary lesions. No sign of epiduritis.
The diagnosis of ADEM secondary to EBV primary infection was made. The initial treatment was discontinued and high-dose corticosteroid 
therapy was started (1 g/day for 5 days) along with ganciclovir. Five days later, medullary MRI showed progression of the lesions, and IV 
immunoglobulins (2 g/kg) were added. This combination achieved a sensitive and motor recovery of the upper extremities.
A control MRI before hospital discharge demonstrated partial regression of the intramedullary hyperintensity (Figs. 2A and 2B). The patient 
was discharged after 2 months, but paraplegia of the lower limbs persisted.
DISCUSSION
ADEM	is	an	inflammatory	and	autoimmune	demyelinating	disease	of	the	central	nervous	system	(CNS)	that	occurs	in	acute	or	sub-acute	
status. It is more common in children than in young adults[1, 2]. The incidence is estimated at 0.4/100,000 individuals per year for children. The 
epidemiological data are not currently available for adults. There seems to be a gender and seasonal preponderance, with a peak in winter 
and spring[3].
A B
European Journal
of Case Reports in
Internal Medicine
DOI: 10.12890/2019_001094 European Journal of Case Reports in Internal Medicine © EFIM 2019
This is an unusual medical condition in adults. In the case presented, the clinical course was marked by an unfavourable and rapid progression 
of the neurological symptoms, in contrast to what has been described in most cases of encephalomyelitis secondary to EBV that has been 
adequately treated.
It typically follows an infectious situation or vaccination. There is often a symptom-free interval of 2 to 30 days between the triggering 
factor	and	the	first	clinical	signs,	as	in	our	case.	Among	the	infectious	agents	involved	in	the	pathogenesis	of	ADEM,	viruses	are	the	most	
common (measles, rubella, chickenpox, cytomegalovirus, herpes simplex virus, EBV) but some bacteria can also be involved (Campylobacter, 
Chlamydia, Legionella, Borrelia burgdorferi, Mycoplasma pneumoniae). Parasites such as Plasmodium and Toxoplasma have been more frequently 
reported in developing countries[4,5,6].
The autoimmune response is probably the result of the homology between the triggering factor (infectious agent, vaccine) and the myelin 
antigen of the host[5,6]. The clinical pattern of ADEM includes general signs such as fever, nausea, vomiting, discomfort and headache, and 
neurological signs such as seizures, focal neurology: hemispheric and/or medullary and altered mental status[7].
Leukocytosis is observed in two-thirds of cases as well as an elevated sedimentation rate. Laboratory investigations must include a complete 
microbiological panel.
CSF studies in ADEM patients often show lymphocytic pleocytosis associated with hyperproteinorachia. A cerebral CT scan (CT) is usually 
normal but an MRI is the gold standard test as it may show multiple and disseminated lesions predominantly in the white matter[8, 9].
In	our	case,	the	diagnosis	of	ADEM	was	confirmed	upon	the	presence	of	typical	lesions,	a	positive	PCR	result	in	the	CSF	and	IgM	for	EBV[10].
A wide range must be considered with respect to the differential diagnosis as conventional treatment for ADEM (high-dose corticosteroids) 
should not be unduly prescribed. 
In the management of this clinical condition, ruling out a CNS infection is a priority; then, empiric anti-infective therapy must be considered 
according	 to	 the	 results.	 Other	 differential	 diagnosis	 possibilities	 include	 inflammatory	 demyelinating	 CNS	 diseases,	 such	 as	 multiple	
sclerosis, isolated clinical syndromes such as optic neuritis, transverse myelitis, leukoencephalopathies, systemic diseases, primary or 
secondary CNS vasculitis and lymphoma[8].
At this time, there has been no randomised study evaluating the optimal treatment of ADEM, including doses and duration of treatment. 
The treatment therefore remains empirical, based mainly on high doses of IV corticosteroids (1 g/day) for 3 to 5 days followed by oral 
administration for 2 to 6 weeks[11].
In the case of resistance or contraindication of corticosteroids, IV immunoglobulins might be considered at doses of 0.4 g/kg/day.
Plasma exchange is a third-line treatment used in cases of refractory forms. The use of antiviral therapy in EBV encephalomyelitis has been 
recommended,	but	its	efficacy	remains	uncertain[11]. With the appropriate treatment, more than 50% of patients treated for ADEM have a 
very good prognostic outcome in contrast with the case hereby presented. 
Figure 2. A. T2-weighted TSE-medial MRI shows 
intramedullary lesions in diffuse hyperintensities 
with atrophy of the cervical-dorsal cord.  
B. After intravenous injection of contrast 
medium, diffuse meningeal enhancement, no 
enhancement of intramedullary lesions.
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Clinical improvement is usually achieved within hours or days after treatment onset. 70% of patients are able to walk without help 7 months 
after the onset. The prognosis is more severe in the case of convulsion or disturbance of consciousness at admission where the mortality 
rate can reach 25%[4].
CONCLUSION
ADEM	should	also	be	considered	in	adults	even	if	it	represents	a	rare	condition	and	MRI	must	be	performed	to	confirm	this,	as	in	the	case	
presented. In the case of no response or a partial response to corticosteroids, IV immunoglobulins should be considered. 
